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1. Data {#sec1}
=======

Concomitant significant CAD was present in 1402 (39.0%) patients. Out of those 622 (17.3%) had a one-vessel, 337 (9.4%) a two-vessel, 310 (8.6%) a three-vessel and 133 (3.7%) left-main disease. Coronary revascularisation either via concomitant coronary artery bypass grafting surgery (443, 31.6%) or via percutaneous coronary intervention (410, 29.2%) was performed in 853 (60.8%) patients.

Occurrence of significant CAD separated by high-sensitivity Troponin T (hsTnT) groups is displayed in [Table 1](#tbl1){ref-type="table"}. Occurrence of CAD was significantly increased in patients with pathological hsTnT (≥14 ng/l; p \< 0.001). For further analysis of the influence of CAD on hsTnT and its prognostic value patients were divided into four groups as following: no significant CAD and normal hsTnT (group 1; n = 862, 25.5%), significant CAD and normal hsTnT (group 2; n = 373, 11.0%), no significant CAD but pathological hsTnT (group 3; n = 1227, 36.3%), significant CAD and pathological hsTnT (group 4, n = 919, 27.2%). Assessment of cardiovascular mortality as well as all-cause mortality by using above mentioned groups is shown in [Fig. 1](#fig1){ref-type="fig"}A, B.Table 1Amount of significantly narrowed coronary arteries separated by hsTnT groups.Table 1No. of coronary arteries narrowedNormal hsTnT (\<14 ng/l)Pathological hsTnT (≥14 ng/l)None862 (69.8%)1227 (57.2%)1181 (14.7%)403 (18.8%)291 (7.4%)220 (10.3%)361 (4.9%)223 (10.4%)Left Main40 (3.2%)73 (3.4%)Fig. 1Kaplan-Meier estimates of cardiovascular (A) and all-cause mortality (B) in patients after aortic valve replacement due to severe stenosis, stratified to pre-procedural high sensitivity troponin t plasma levels by using a cut-off point at 14 ng/l and the prevalence of coronary artery disease.Fig. 1

Three-vessel disease was found in 284 patients of whom 61 had normal hsTnT and 223 had elevated hsTnT. Kaplan-Meier curves for the prediction of cardiovascular and all-cause mortality by using the hsTnT groups in patients with three-vessel disease are presented in [Fig. 2](#fig2){ref-type="fig"}A, B. The ROC curves of N-terminal pro brain natriuretic peptide (NT-proBNP) and hsTnT on all-cause mortality are displayed in [Fig. 3](#fig3){ref-type="fig"}. The Youden index, which describes the most sensitive and specific value for the prediction of mortality, was detected to be at 1295 ng/l for NT-proBNP and at 25 ng/l for hsTnT. The cox regression hazard model on cardiovascular mortality is presented in [Table 2](#tbl2){ref-type="table"}.Fig. 2Kaplan-Meier estimates of cardiovascular (A) and all-cause mortality (B) in patients with three-vessel coronary artery disease after aortic valve replacement due to severe stenosis, stratified to pre-procedural high sensitivity troponin t plasma levels by using a cut-off point at 14 ng/l.Fig. 2Fig. 3Receiver operating characteristic curve for the evaluation of the predictive value of pre-procedural high sensitivity troponin t and N-terminal pro brain natriuretic peptide plasma levels on all-cause mortality.Fig. 3Table 2Multivariate cox regression analysis for cardiovascular mortality.Table 2VariableHR (95% CI)*P* value for heterogenityhsTnT (\<14 ng/l as reference)1.234 (0.940--1.621)0.130NT-proBNP (normal range as reference)1.408 (1.026--1.933)0.034LVEF (\>50% as reference) LVEF (30--50%)1.087 (0.865--1.365)0.474 LVEF (\<30%)1.825 (1.265--2.632)0.001Age1.051 (1.032--1.070)\<0.001CAD1.188 (0.976--1.445)0.085Male gender0.950 (0.773--1.168)0.629Arterial hypertension1.104 (0.848--1.437)0.464Atrial fibrillation1.813 (1.493--2.201)\<0.001eGFR0.991 (0.987--0.996)\<0.001COPD1.287 (1.001--1.654)0.049Diabetes mellitus1.115 (0.892--1.393)0.339STS-PROM score (\<3% as reference) 3 -- \<8%0.987 (0.757--1.287)0.922 8 -- \<15%1.059 (0.678--1.656)0.801 ≥15%0.991 (0.228--4.301)0.991TAVR (SAVR as reference)1.812 (1.416--2.320)\<0.001[^1]

2. Experimental design, materials, and methods {#sec2}
==============================================

Data was acquired locally at each of the contributing hospitals in a retrospective way by using the electronic hospital information system or the electronic patient record. Patients were enrolled consecutively at all participating centers, inclusion and exclusion criteria were described in the main publication \[[@bib1]\]. Then, it was paired with prospective data on mortality and cause of death defined by ICD-10 codes. This data was obtained by "Statistics Austria", the governmental statistic department.

Severitiy of aortic valve stenosis was graded according to current guidelines \[[@bib2]\]. The coronary anatomic status was assessed by using coronary angiography in every patient as part of the diagnostic examination prior to valve replacement. Significant CAD was defined as a stenosis of at least 70% or previously performed coronary intervention including CABG. In case of a transcutaneous aortic valve replacement, percutaneous coronary intervention was performed in advance during a separated hospital stay. Revascularisation by coronary artery bypass grafting was conducted as part of the aortic valve replacement surgery.

Chi-square tests were used for the assessment of differences in the prevalence of CAD and hsTnT groups. Analysis of survival was performed by using either the Kaplan-Meier method (univariate) or a cox regression hazard model (multivariate). Calculations were conducted with IBM SPSS version 24 (IBM Corporation, Armonk, NY, USA). Graphics were designed by using GraphPad PRISM, version 5 (GraphPad Software, Inc., La Jolla, CA, USA).
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[^1]: Abbreviations: CAD, coronary artery disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; hsTnT, high sensitivity troponin T; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro brain natriuretic peptide; SAVR, surgical aortic valve replacement; STS-PROM score, Society of Thoracic Surgeons predicted risk of mortality score; TAVR, transcatheter aortic valve replacement.
